Moreover, the ex vivo-differentiated, olaparib-treated macrophages had a greater ability to kill K14-Cre BRCA1f/fp53f/f BC cells than their controls (Figure 2D), and that required at least 4 days of ex vivo differentiation to develop (Figure S2B). This evidence concerns the gene KRT14 and breast cancer.